The BRAF V600E mutation plays a central role in modulating therapeutic response in thyroid cancers, notably by activating the MAPK pathway, which suppresses key proteins involved in iodine uptake, such as the sodium–iodide symporter and the TSH receptor. This evidence concerns the gene BRAF and thyroid cancer.